ESSA Pharma Inc. (EPIX) Research

ESSA Pharma Inc. (EPIX) functions as a clinical-stage pharmaceutical firm, concentrating its efforts on developing innovative and exclusive therapies designed to combat prostate cancer. The company's primary drug candidate is EPI-7386, an oral treatment presently undergoing Phase I clinical trials. This investigational compound is intended for individuals suffering from metastatic castration-resistant prostate cancer. Furthermore, ESSA Pharma has established collaborative partnerships with organizations including Caris Life Sciences, Inc., Bayer Consumer Care AG, Janssen Research & Development, LLC, and Astellas Pharma Inc. Founded in 2009, the company's corporate offices are located in Vancouver, Canada.

Market snapshot

Symbol
EPIX
Price
$0.20
Day change
-1.85%
Market cap
$9.5M
P/E ratio
-0.47x
52-week range
0.18-6.45
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$9.50

Peer companies

  • Apexigen, Inc. (APGN)
  • Biora Therapeutics, Inc. (BIOR)
  • Channel Therapeutics Corporation (CHRO)
  • CervoMed Inc. (CRVO)
  • COSCIENS Biopharma Inc. (CSCI)
  • IMV Inc. (IMVIF)
  • Korro Bio, Inc. (KRRO)
  • Scorpius Holdings, Inc. (SCPX)

Recent insider activity

  • Parkinson David Ross — D-Return (65675 shares) on 2025-10-09
  • Wood David S. — D-Return (33343 shares) on 2025-10-09
  • BERGER FRANKLIN M — D-Return (784404 shares) on 2025-10-09
  • Glickman Richard M — D-Return (43240 shares) on 2025-10-09
  • Requadt Scott — D-Return (30002 shares) on 2025-10-09

Open ESSA Pharma Inc. (EPIX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.